Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

padeliporfin 5Nivolumab 5Ipilimumab 4Sunitinib 3Specimen Handling 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Abiraterone Acetate 3pembrolizumab 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2abiraterone 2Surveys and Questionnaires 2Radiation Dose Hypofractionation 2Pluvicto 2Paclitaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2vinflunine 1valrubicin 1tislelizumab 1temsirolimus 1sipuleucel-T 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Lutetium-177 × Genitourinary × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡